MCK MCKESSON CORP
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 927653 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY16.5%
TTM EPS YoY21.1%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR10.5%
Margins
Gross margin3.7%
Operating margin1.6%
Net margin1.1%
FCF margin1.7%
EBITDA margin1.7%
Returns
ROE—
ROA5.3%
ROIC (approx.)1,481.2%
Asset turnover4.75x
Leverage & solvency
Liabilities / assets101.1%
Debt / equity—
Current ratio0.90x
Interest coverage21.87x
Cash quality & payout
Operating cash flow / net income1.60x
Accruals ratio-3.2%
Payout ratio8.5%
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $403.43B | $359.05B |
| Cost of revenue | $388.88B | $345.73B |
| Gross profit | $14.55B | $13.32B |
| SG&A expense | $8.10B | $8.51B |
| Operating income | $6.21B | $4.42B |
| Interest expense | $247.00M | $265.00M |
| Pretax income | $6.20B | $4.36B |
| Income tax | $1.10B | $878.00M |
| Net income | $4.76B | $3.29B |
| EBITDA | $6.50B | $4.69B |
| EPS (basic) | 38.55 | 25.86 |
| EPS (diluted) | 38.38 | 25.72 |
| Dividends declared per share | 3.17 | 2.75 |
| Weighted avg. shares (diluted) | 124.10M | 128.10M |
| Balance sheet | ||
| Cash & equivalents | $3.98B | $5.96B |
| Receivables | $27.98B | $25.64B |
| Inventory | $24.21B | $23.00B |
| Current assets | $57.21B | $55.40B |
| PP&E, net | $2.67B | $2.50B |
| Goodwill | $11.32B | $10.02B |
| Intangibles | $4.08B | $1.46B |
| Total assets | $82.32B | $75.14B |
| Current liabilities | $67.02B | $61.60B |
| Short-term debt | $1.27B | $1.19B |
| Long-term debt | $5.26B | $4.46B |
| Total debt | $6.53B | $5.65B |
| Total liabilities | $83.16B | $76.83B |
| Shareholders' equity | -$2.17B | -$2.07B |
| Net debt | $2.55B | -$302.00M |
| Cash flow statement | ||
| Operating cash flow | $6.16B | $6.08B |
| Capital expenditure | $436.00M | $537.00M |
| Free cash flow | $5.72B | $5.55B |
| Investing cash flow | -$3.43B | -$733.00M |
| Financing cash flow | -$4.63B | -$3.96B |
| Depreciation & amortization | $287.00M | $272.00M |
| Stock-based compensation | $247.00M | $226.00M |
| Dividends paid | $381.00M | $345.00M |
| Share buybacks | $4.75B | $3.15B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.